IN2014DN09134A - - Google Patents

Info

Publication number
IN2014DN09134A
IN2014DN09134A IN9134DEN2014A IN2014DN09134A IN 2014DN09134 A IN2014DN09134 A IN 2014DN09134A IN 9134DEN2014 A IN9134DEN2014 A IN 9134DEN2014A IN 2014DN09134 A IN2014DN09134 A IN 2014DN09134A
Authority
IN
India
Prior art keywords
mir
compositions
activity
fibrosis
inhibition
Prior art date
Application number
Inventor
Balkrishen Bhat
Eric Marcusson
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of IN2014DN09134A publication Critical patent/IN2014DN09134A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Abstract

Described herein are compositions and methods for the inhibition of miR 21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR 21 activity. The compositions may be used to inhibit miR 21 and also to treat diseases associated with abnormal expression of miR 21 such as fibrosis and cancer.
IN9134DEN2014 2012-04-25 2013-04-24 IN2014DN09134A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261741783P 2012-04-25 2012-04-25
US201261717927P 2012-10-24 2012-10-24
US201361779913P 2013-03-13 2013-03-13
PCT/US2013/037913 WO2013163258A1 (en) 2012-04-25 2013-04-24 Microrna compounds and methods for modulating mir-21 activity

Publications (1)

Publication Number Publication Date
IN2014DN09134A true IN2014DN09134A (en) 2015-05-22

Family

ID=48289681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9134DEN2014 IN2014DN09134A (en) 2012-04-25 2013-04-24

Country Status (29)

Country Link
US (5) US8969317B2 (en)
EP (1) EP2841579B1 (en)
JP (1) JP6322189B2 (en)
KR (4) KR102118429B1 (en)
CN (1) CN104254607B (en)
AR (1) AR090825A1 (en)
AU (1) AU2013251696B2 (en)
BR (1) BR112014026639A8 (en)
CA (1) CA2869639A1 (en)
CL (3) CL2014002844A1 (en)
CO (1) CO7111303A2 (en)
CR (1) CR20140524A (en)
DO (1) DOP2014000233A (en)
EA (1) EA030211B1 (en)
EC (1) ECSP14028612A (en)
GT (1) GT201400221A (en)
HK (1) HK1207115A1 (en)
IL (1) IL234904B (en)
IN (1) IN2014DN09134A (en)
MX (1) MX353562B (en)
MY (1) MY173600A (en)
NZ (1) NZ630591A (en)
PE (1) PE20142404A1 (en)
PH (1) PH12014502387A1 (en)
SG (1) SG11201406931XA (en)
TW (1) TWI647235B (en)
UA (1) UA117098C2 (en)
WO (1) WO2013163258A1 (en)
ZA (1) ZA201407228B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN113151272A (en) 2011-04-25 2021-07-23 赛诺菲 microRNA compounds and methods for modulating MIR-21 activity
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243950A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides
JP2015518475A (en) * 2012-04-10 2015-07-02 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） Treatment method for nonalcoholic steatohepatitis
TWI647235B (en) 2012-04-25 2019-01-11 美商雷格勒斯治療公司 MicroRNA (MICRORNA) compounds and methods for modulating MIR-21 activity
UA116639C2 (en) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Methods for treatment of alport syndrome
DK2906256T3 (en) * 2012-10-12 2018-11-19 Ionis Pharmaceuticals Inc SELECTIVE ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015061536A1 (en) 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
US20160289678A1 (en) * 2013-11-22 2016-10-06 Dcb-Usa Llc Use of microrna 146-a in the diagnosis, treatment and prevention of picornavirus infection and microrna 146-a antagonists
EP3105327A4 (en) * 2014-02-12 2017-10-18 Thomas Jefferson University Compositions and methods of using microrna inhibitors
US9833416B2 (en) * 2014-04-04 2017-12-05 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
CN105087477A (en) * 2015-05-21 2015-11-25 王松灵 Application of mesenchymal stem cell modified by miR-21 antisense nucleotide
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
JP2019535839A (en) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー Exosomes for the delivery of therapeutic agents
KR20190141770A (en) * 2017-05-04 2019-12-24 사노피 Treatment of Alport Syndrome
WO2020038968A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
US20220096517A1 (en) * 2018-11-13 2022-03-31 Regulus Therapeutics Inc. MicroRNA Compounds and Methods for Modulating MIR-10B Activity
JPWO2021020412A1 (en) 2019-07-30 2021-02-04
KR102293777B1 (en) * 2019-12-31 2021-08-25 연세대학교 산학협력단 A Novel UQCRB-related Circulating miRNA Biomarker and a Method for Diagnosing Colorectal Cancer Using the Same
AU2021252156A1 (en) * 2020-04-09 2022-11-03 Technische Universität München Targeted delivery of an inhibitor of miR-21 to macrophages for the treatment of pulmonary fibrosis
KR102328770B1 (en) * 2020-06-01 2021-11-19 고려대학교 산학협력단 Biomaker miRNA-4449 for diagnosing nonalcoholic steatohepatitis
KR102360963B1 (en) * 2020-07-28 2022-02-09 고려대학교 산학협력단 Biomarker for the diagnosis of nonalcoholic steatohepatitis using circulating microRNA combination
EP4221710A1 (en) * 2020-10-01 2023-08-09 University of Washington Drug-like molecules and methods for the therapeutic targeting of microrna-21

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003432T2 (en) 1998-05-22 2001-03-21 Boys Town National Research Hospital TGF-beta1 inhibitors for the treatment of kidney disease and the use of alpha1beta1 binding receptor inhibitors.
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
EP2290067B1 (en) 2004-05-28 2014-12-10 Asuragen, Inc. Methods and compositions involving microRNA
EP2990410A1 (en) 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
JP2008512463A (en) 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル Treatment of glomerular basement membrane disease associated with matrix metalloproteinase-12
ES2534302T3 (en) 2004-11-12 2015-04-21 Asuragen, Inc. Procedures and compositions involving miRNA and miRNA inhibitor molecules
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
EP2338992A3 (en) * 2005-08-29 2011-10-12 Regulus Therapeutics, Inc Antisense compounds having enhanced anti-microRNA activity
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
EP2388327A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
CA3024953A1 (en) * 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
MY162210A (en) 2006-04-03 2017-05-31 Roche Innovation Ct Copenhagen As Pharmaceutical composition
ES2430206T3 (en) 2006-10-03 2013-11-19 Tekmira Pharmaceuticals Corporation Formulation containing lipids
EP2476762B1 (en) 2006-10-09 2014-01-08 Julius-Maximilians-Universität Würzburg Micro-RNA (miRNA) for diagnosing and treating heart disease
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (en) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
JP6035010B2 (en) * 2007-10-04 2016-11-30 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Micro MIR
EP2217248B1 (en) 2007-10-29 2016-11-30 Regulus Therapeutics Inc. Targeting micrornas for the treatment of liver cancer
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
JP2012518997A (en) * 2009-02-26 2012-08-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA in smoking inexperienced persons and related materials and methods
MA33488B1 (en) * 2009-06-08 2012-08-01 Miragen Therapeutics CHEMICAL MODIFICATION RULES FOR INHIBITORS AND MIMETICS OF MIRIK
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
CN113151272A (en) * 2011-04-25 2021-07-23 赛诺菲 microRNA compounds and methods for modulating MIR-21 activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
TWI647235B (en) 2012-04-25 2019-01-11 美商雷格勒斯治療公司 MicroRNA (MICRORNA) compounds and methods for modulating MIR-21 activity
MX355408B (en) 2012-06-21 2018-04-18 Miragen Therapeutics Inc Oligonucleotide-based inhibitors comprising locked nucleic acid motif.
CA2886116C (en) 2012-09-26 2022-06-07 Mirrx Therapeutics Oligomers with improved off-target profile
UA116639C2 (en) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Methods for treatment of alport syndrome

Also Published As

Publication number Publication date
CN104254607B (en) 2020-10-27
JP6322189B2 (en) 2018-05-09
MX2014012476A (en) 2014-12-08
US20130289093A1 (en) 2013-10-31
KR102369722B1 (en) 2022-03-04
CL2019001878A1 (en) 2019-12-06
US9688985B2 (en) 2017-06-27
US20170240891A1 (en) 2017-08-24
EP2841579B1 (en) 2018-10-10
GT201400221A (en) 2018-01-17
US8969317B2 (en) 2015-03-03
IL234904B (en) 2019-10-31
HK1207115A1 (en) 2016-01-22
KR102118429B1 (en) 2020-06-03
JP2015519891A (en) 2015-07-16
BR112014026639A8 (en) 2018-01-16
US20180305691A1 (en) 2018-10-25
EA030211B1 (en) 2018-07-31
CL2017001195A1 (en) 2018-01-26
ZA201407228B (en) 2017-05-31
TWI647235B (en) 2019-01-11
US9970009B2 (en) 2018-05-15
US20150218558A1 (en) 2015-08-06
KR20150003846A (en) 2015-01-09
MY173600A (en) 2020-02-08
AU2013251696B2 (en) 2018-11-15
CL2014002844A1 (en) 2015-02-13
CO7111303A2 (en) 2014-11-10
DOP2014000233A (en) 2014-12-31
AR090825A1 (en) 2014-12-10
AU2013251696A1 (en) 2014-10-16
US20160244753A1 (en) 2016-08-25
KR20230037703A (en) 2023-03-16
PH12014502387A1 (en) 2014-12-22
TW201345918A (en) 2013-11-16
SG11201406931XA (en) 2014-11-27
CA2869639A1 (en) 2013-10-31
KR20200064164A (en) 2020-06-05
IL234904A0 (en) 2014-12-31
EP2841579A1 (en) 2015-03-04
NZ630591A (en) 2017-02-24
KR20220028183A (en) 2022-03-08
EA201491953A1 (en) 2015-06-30
WO2013163258A1 (en) 2013-10-31
UA117098C2 (en) 2018-06-25
MX353562B (en) 2018-01-17
PE20142404A1 (en) 2015-02-02
ECSP14028612A (en) 2015-09-30
CR20140524A (en) 2015-02-12
US9267137B2 (en) 2016-02-23
BR112014026639A2 (en) 2017-06-27
CN104254607A (en) 2014-12-31

Similar Documents

Publication Publication Date Title
IN2014DN09134A (en)
AU2018236800B2 (en) DNA-PK inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2022000212A (en) Microrna compounds and methods for modulating mir-21 activity.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
NZ700928A (en) Dna-pk inhibitors
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (en) Nampt inhibitors.
IN2015DN01151A (en)
MX2017004618A (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases.
MX353299B (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer.
MX348311B (en) Nampt inhibitors.
MX2014013758A (en) Thiazolecarboxamide derivatives for use as nampt inhibitors.
IN2014DN08443A (en)
TN2014000401A1 (en) Microrna compounds and methods for modulating mir-21 activity
MY192305A (en) Bipyrazole derivatives as jak inhibitors